Anti-VEGF Receptor 2 (phospho Y951) antibody (ab38473)
Key features and details
- Rabbit polyclonal to VEGF Receptor 2 (phospho Y951)
- Suitable for: WB, IHC-P
- Reacts with: Human
- Isotype: IgG
Overview
-
Product name
Anti-VEGF Receptor 2 (phospho Y951) antibody
See all VEGF Receptor 2 primary antibodies -
Description
Rabbit polyclonal to VEGF Receptor 2 (phospho Y951) -
Host species
Rabbit -
Specificity
This antibody is specific for VEGF Receptor 2 only when phosphorylated at tyrosine 951. -
Tested applications
Suitable for: WB, IHC-Pmore details -
Species reactivity
Reacts with: Human
Predicted to work with: Mouse
-
Immunogen
Synthetic phosphopeptide derived from Human VEGF Receptor 2 around the phosphorylation site of tyrosine 951.
-
Positive control
- WB: SK-OV3 cell extract. IHC-P: Breast carcinoma tissue.
-
General notes
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles. -
Storage buffer
pH: 7.40
Preservative: 0.02% Sodium azide
Constituents: 50% Glycerol, 0.87% Sodium chloride, PBS -
Concentration information loading... -
Purity
Immunogen affinity purified -
Purification notes
The antibody was affinity purified from rabbit antiserum by affinity chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site. -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Associated products
-
Compatible Secondaries
-
Conjugation kits
-
Isotype control
-
Recombinant Protein
Applications
Our Abpromise guarantee covers the use of ab38473 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| WB | 1/500 - 1/1000. Detects a band of approximately 190 kDa (predicted molecular weight: 151 kDa). | |
| IHC-P | 1/50 - 1/100. |
Target
-
Function
Receptor for VEGF or VEGFC. Has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions. -
Involvement in disease
Defects in KDR are associated with susceptibility to hemangioma capillary infantile (HCI) [MIM:602089]. HCI are benign, highly proliferative lesions involving aberrant localized growth of capillary endothelium. They are the most common tumor of infancy, occurring in up to 10% of all births. Hemangiomas tend to appear shortly after birth and show rapid neonatal growth for up to 12 months characterized by endothelial hypercellularity and increased numbers of mast cells. This phase is followed by slow involution at a rate of about 10% per year and replacement by fibrofatty stroma. -
Sequence similarities
Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.
Contains 7 Ig-like C2-type (immunoglobulin-like) domains.
Contains 1 protein kinase domain. -
Post-translational
modificationsPhosphorylated. Dephosphorylated by PTPRB. Dephosphorylated by PTPRJ at Tyr-951, Tyr-996, Tyr-1054, Tyr-1059, Tyr-1175 and Tyr-1214. -
Cellular localization
Membrane. - Information by UniProt
-
Database links
- Entrez Gene: 3791 Human
- Entrez Gene: 16542 Mouse
- Omim: 191306 Human
- SwissProt: P35968 Human
- SwissProt: P35918 Mouse
- Unigene: 479756 Human
- Unigene: 285 Mouse
-
Alternative names
- CD309 antibody
- CD309 antigen antibody
- EC 2.7.10.1 antibody
see all
Images
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-VEGF Receptor 2 (phospho Y951) antibody (ab38473)ab38473 at a 1:50 dilution staining VEGF Receptor 2 in Human breast carcinoma tissue using Immunohistochemistry, Paraffin Embedded Tissue.
Left image : untreated.
Right image : treated with phosphopeptide.
-
Western blot - Anti-VEGF Receptor 2 (phospho Y951) antibody (ab38473)All lanes : Anti-VEGF Receptor 2 (phospho Y951) antibody (ab38473)
Lane 1 : SK-OV-3 (Human ovarian cancer cell line) cell lysate. Treated with phosphopeptide
Lane 2 : SK-OV-3 (Human ovarian cancer cell line) cell lysate
Predicted band size: 151 kDa
Observed band size: 230 kDa why is the actual band size different from the predicted?VEGFR2 is translated into a 150 kDa protein. Glycosylation of the extracellular domain results in the mature form at the cell surface which migrates at 230 kDa via western blot.
Protocols
Datasheets and documents
References (7)
ab38473 has been referenced in 7 publications.
- Li C et al. HIF-1a/VEGF signaling-mediated epithelial-mesenchymal transition and angiogenesis is critically involved in anti-metastasis effect of luteolin in melanoma cells. Phytother Res 33:798-807 (2019). PubMed: 30653763
- Huang M et al. Apatinib affect VEGF-mediated cell proliferation, migration, invasion via blocking VEGFR2/RAF/MEK/ERK and PI3K/AKT pathways in cholangiocarcinoma cell. BMC Gastroenterol 18:169 (2018). PubMed: 30400838
- Zhao G et al. The Soluble VEGF Receptor sFlt-1 Contributes to Impaired Neovascularization in Aged Mice. Aging Dis 8:287-300 (2017). PubMed: 28580185
- Kapur S et al. Engineered ligand-based VEGFR antagonists with increased receptor binding affinity more effectively inhibit angiogenesis. Bioeng Transl Med 2:81-91 (2017). WB . PubMed: 28516164
- Zhang W et al. Combined aspirin and apatinib treatment suppresses gastric cancer cell proliferation. Oncol Lett 14:5409-5417 (2017). PubMed: 29142602
- Koyama Y et al. Endothelin-1 increases the expression of VEGF-R1/Flt-1 receptors in rat cultured astrocytes through ETB receptors. J Neurochem 130:759-69 (2014). PubMed: 24862165
- Sangaletti S et al. Macrophage-derived SPARC bridges tumor cell-extracellular matrix interactions toward metastasis. Cancer Res 68:9050-9 (2008). IHC-P ; Mouse . PubMed: 18974151
